Modulation of the CD4+ T cell response after acellular pertussis vaccination in the presence of TLR4 ligation

Vaccine

Volumn 33, Issue 12, 2015, Pages 1483-1491

  Brummelman, Jolanda ^a   Helm, Kina ^a   Hamstra, Hendrik Jan ^a   van der Ley, Peter ^b   Boog, Claire J P ^b   Han, Wanda G H ^a   van Els, Cécile A C M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Intravacc (Institute for Translational Vaccinology)   (Netherlands)

Author keywords

Acellular pertussis vaccine; Adjuvants; Bordetella pertussis; CD4 T cells; Memory T cells; TLR4

Indexed keywords

CD4 ANTIGEN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE LPXL1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERTUSSIS VACCINE; TETRAMER; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD; BORDETELLA PERTUSSIS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOMODULATION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION; ANIMAL; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHENOTYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MICE; PHENOTYPE; TH1 CELLS; TH17 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 4;

EID: 84924517932     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.063     Document Type: Article

References (42)

1. Black A.J., McKane A.J. Stochasticity in staged models of epidemics: quantifying the dynamics of whooping cough. J R Soc Interface 2010, 7:1219-1227.
2. Cherry J.D. The present and future control of pertussis. Clin Infect Dis 2010, 51:663-667.
3. Pertussis vaccines WHO position paper. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations=Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations 2010, 85:385-400.
4. Liko J., Robison S.G., Cieslak P.R. Priming with whole-cell versus acellular pertussis vaccine. New Eng. J Med 2013, 368:581-582.
5. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA: J Am Med Assoc 2012, 308:454-456.
6. Redhead K., Watkins J., Barnard A., Mills K.H. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993, 61:3190-3198.
7. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007, 25:391-398.
8. Hendrikx L.H., Schure R.M., Ozturk K., de Rond L.G., de Greeff S.C., Sanders E.A., et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine 2011, 29:6874-6880.
9. Vermeulen F., Verscheure V., Damis E., Vermeylen D., Leloux G., Dirix V., et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol 2010, 17:258-262.
10. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular Pertussis vaccine. PLoS Pathog 2013, 9:e1003264.
11. Leef M., Elkins K.L., Barbic J., Shahin R.D. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med 2000, 191:1841-1852.
12. Ryan M., Murphy G., Gothefors L., Nilsson L., Storsaeter J., Mills K.H. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997, 175:1246-1250.
13. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61:399-410.
14. Geurtsen J., Banus H.A., Gremmer E.R., Ferguson H., de la Fonteyne-Blankestijn L.J., Vermeulen J.P., et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol 2007, 14:821-829.
15. Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
16. Sarkar S., Teichgraber V., Kalia V., Polley A., Masopust D., Harrington L.E., et al. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J Immunol 2007, 179:6704-6714.
17. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
18. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
19. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262.
20. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003, 4:835-842.
21. van der Ley P., Steeghs L., Hamstra H.J., ten Hove J., Zomer B., van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001, 69:5981-5990.
22. Arenas J., van Dijken H., Kuipers B., Hamstra H.J., Tommassen J., van der Ley P. Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity. Clin Vaccine Immunol 2010, 17:487-495.
23. Stenger R.M., Poelen M.C., Moret E.E., Kuipers B., Bruijns S.C., Hoogerhout P., et al. Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun 2009, 77:896-903.
24. Hijnen M., van Gageldonk P.G., Berbers G.A., van Woerkom T., Mooi F.R. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expression Purif 2005, 41:106-112.
25. Stenger R.M., Smits M., Kuipers B., Kessen S.F., Boog C.J., van Els C.A. Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens. Clin Vaccine Immunol 2011, 18:595-603.
26. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
27. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
28. Mosmann T.R., Kobie J.J., Lee F.E., Quataert S.A. T helper cytokine patterns: defined subsets, random expression, and external modulation. Immunol Res. 2009, 45:173-184.
29. Barton G.M., Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002, 14:380-383.
30. Bortolatto J., Borducchi E., Rodriguez D., Keller A.C., Faquim-Mauro E., Bortoluci K.R., et al. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis. Clin Exp Allergy 2008, 38:1668-1679. journal of the British Society for Allergy and Clinical Immunology.
31. Franchi L., Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008, 38:2085-2089.
32. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
33. Hall J.G., Morris B. The immediate effect of antigens on the cell output of a lymph node. Brit J Exp Pathol 1965, 46:450-454.
34. Cahill R.N., Frost H., Trnka Z. The effects of antigen on the migration of recirculating lymphocytes through single lymph nodes. J Exp Med 1976, 143:870-888.
35. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
36. Bienzle U., Gunther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811-819.
37. Schwarz T.F., Huang L.M., Medina D.M., Valencia A., Lin T.Y., Behre U., et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolescent Health 2012, 50:187-194. official publication of the Society for Adolescent Medicine.
38. Ireton G.C., Reed S.G. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands. Expert Rev of Vaccines 2013, 12:793-807.
39. Bryant C.E., Monie T.P. Mice, men and the relatives: cross-species studies underpin innate immunity. Open Biol 2012, 2:120015.
40. Geurtsen J., Steeghs L., Hamstra H.J., Ten Hove J., de Haan A., Kuipers B., et al. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun 2006, 74:5574-5585.
41. Dunne A., Mielke L.A., Allen A.C., Sutton C.E., Higgs R., Cunningham C.C., et al. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol 2014, [Epub ahead of print]. 10.1038/mi.2014.93.
42. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.